F-star Biotechnology Ltd. is a biotechnology company, founded in Vienna in 2006,[1] with a current main research site in Cambridge, UK. The company is focused in developing bispecific monoclonal antibodies using a modular combinatorial approach that engineers the Fc constant region of an immunoglobulin into a novel antigen-binding site.[2][3]
| Industry | Pharmaceutical |
|---|---|
| Headquarters | Cambridge, UK |
| Website | www.f-star.com |
See also
edit- ^ "F-star starts its operations" (PDF). F-Star. 12 June 2006. Retrieved 12 December 2016.
- ^ "Home". f-star.com.
- ^ Wozniak-Knopp G, Bartl S, Bauer A, Mostageer M, Woisetschläger M, Antes B, Ettl K, Kainer M, Weberhofer G, Wiederkum S, Himmler G, Mudde GC, Rüker F (2010). "Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties". Protein Eng Des. 23 (4): 289–297. doi:10.1093/protein/gzq005. PMID 20150180.